BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24289126)

  • 1. Recent developments in chemotherapy for meningiomas: a review.
    Moazzam AA; Wagle N; Zada G
    Neurosurg Focus; 2013 Dec; 35(6):E18. PubMed ID: 24289126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Therapeutic Strategies in the Treatment of Meningioma.
    Caruso G; Elbabaa SK; Gonzalez-Lopez P; Barresi V; Passalacqua M; Caffo M
    Anticancer Res; 2015 Dec; 35(12):6391-400. PubMed ID: 26637848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment of recurrent meningiomas.
    Chamberlain MC; Barnholtz-Sloan JS
    Expert Rev Neurother; 2011 Oct; 11(10):1425-32. PubMed ID: 21955199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy: What is its role in meningioma?
    Sherman WJ; Raizer JJ
    Expert Rev Neurother; 2012 Oct; 12(10):1189-95; quiz 1196. PubMed ID: 23082735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
    Chamberlain MC
    Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies for meningiomas.
    Wen PY; Drappatz J
    Expert Rev Neurother; 2006 Oct; 6(10):1447-64. PubMed ID: 17078786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade meningiomas: new avenues for drug treatment?
    Preusser M; Berghoff AS; Hottinger AF
    Curr Opin Neurol; 2013 Dec; 26(6):708-15. PubMed ID: 24184974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea chemotherapy in the treatment of meningiomas.
    Newton HB
    Neurosurg Focus; 2007; 23(4):E11. PubMed ID: 17961035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
    Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
    Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas.
    Ragel BT; Couldwell WT; Wurster RD; Jensen RL
    Neurosurg Focus; 2007; 23(4):E10. PubMed ID: 17961034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted drug therapy for meningiomas.
    Norden AD; Drappatz J; Wen PY
    Neurosurg Focus; 2007; 23(4):E12. PubMed ID: 17961036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
    Karsy M; Guan J; Cohen A; Colman H; Jensen RL
    Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
    Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of high risk or recurrent meningiomas with hydroxyurea.
    Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2002 Mar; 9(2):156-8. PubMed ID: 11922703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
    Newton HB; Scott SR; Volpi C
    Br J Neurosurg; 2004 Oct; 18(5):495-9. PubMed ID: 15799152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.